6-[(N-2,3-Dichlorophenyl)amino]-7-chloro-5,8-quinolinedione treatment of candidiasis in normal mice

Abstract

6-[(N-2,3-Dichlorophenyl)amino]-7-chloro-5,8-quinolinedione (RCK11) was tested for in vivo antifungal activities in the treatment of systemic infection with Candida albicans in normal mice compared with ketoconazole. The therapeutic potential of RCK11 had been assessed by evaluating their activities (survival rates) against systemic infections in normal mice. ED50 of intraperitoneally administered RCK11 was 0.10±0.01 mg/kg but that of ketoconazole had 8. 00±0.73 mg/kg respectively. When RCK11 was administered intravenously at the ED50 (0.10 mg/kg), the colony counts of Candida albicans in the liver after 7 days and 14 days were reduced as likely as ketoconazole at the ED50 (8.00 mg/kg), and the better survival rates than ketoconazole were achieved after 14 days. The results suggest that RCK11 may be a potent antifungal agent.